Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 19/20 | 1.00 |
| ▸ | PDE10A | Q9Y233 | 13/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.42 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.42 |
| ▸ | PDE6D | O43924 | 1/20 | 0.41 |
| ▸ | PDE6A | P16499 | 1/20 | 0.41 |
| ▸ | PDE6G | P18545 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | PDE6B | P35913 | 1/20 | 0.41 |
| ▸ | PDE6C | P51160 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.41 |
| ▸ | PDE6H | Q13956 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14764543 | 0.99 | PDE2A (0.98) | PDE2APDE10AKDM4EPDE4DPDE11A | |
| SCHEMBL14764772 | 0.94 | PDE2A (0.88) | PDE2APDE10AKDM4EPDE4DPDE11A | |
| SCHEMBL14764289 | 0.91 | PDE2A (0.83) | PDE2APDE10APDE4DPDE6DPDE6A | |
| SCHEMBL14764467 | 0.81 | PDE2A (0.70) | PDE2APDE10A | |
| SCHEMBL14764364 | 0.78 | PDE2A (0.64) | PDE2APDE10A | |
| SCHEMBL15961858 | 0.77 | PDE2A (1.00) | PDE2APDE10AKDM4EPDE4DPDE11A | |
| SCHEMBL15961862 | 0.77 | PDE2A (0.62) | PDE2APDE10APDE4DPDE11APDE4A | |
| SCHEMBL14765049 | 0.76 | PDE2A (0.64) | PDE2APDE10AKDM4EPDE4DPDE6D | |
| SCHEMBL14764577 | 0.74 | PDE2A (0.74) | PDE2APDE10A | |
| SCHEMBL15953391 | 0.72 | PDE2A (0.56) | PDE2APDE10APDE4DPDE6DPDE6A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140235645-A1 | Pyridine Compounds and Uses Thereof | H. LUNDBECK A/S (DK) | 2014-08-21 | — | — | US | claimed |
| US-9056863-B2 | Substituted 2,3,5,9,9B-pentaazacyclopenta[a]naphthalenes and uses thereof | H. LUNDBECK A/S (DK) | 2015-06-16 | — | — | US | disclosed |
| US-9056863-B2 | Substituted 2,3,5,9,9B-pentaazacyclopenta[a]naphthalenes and uses thereof | H. LUNDBECK A/S (DK) | 2015-06-16 | — | — | US | disclosed |
| US-9056863-B2 | Substituted 2,3,5,9,9B-pentaazacyclopenta[a]naphthalenes and uses thereof | H. LUNDBECK A/S (DK) | 2015-06-16 | — | — | US | disclosed |
| US-20140235645-A1 | Pyridine Compounds and Uses Thereof | H. LUNDBECK A/S (DK) | 2014-08-21 | — | — | US | disclosed |
| US-20140235645-A1 | Pyridine Compounds and Uses Thereof | H. LUNDBECK A/S (DK) | 2014-08-21 | — | — | US | disclosed |
| US-20140235645-A1 | Pyridine Compounds and Uses Thereof | H. LUNDBECK A/S (DK) | 2014-08-21 | — | — | US | disclosed |
| EP-2763989-A1 | PYRIDINE COMPOUNDS AND USES THEREOF | H. Lundbeck A/S (DK) | 2014-08-13 | — | — | EP | disclosed |
| WO-2013034761-A1 | PYRIDINE COMPOUNDS AND USES THEREOF | H. LUNDBECK A/S (DK) | 2013-03-14 | — | — | WO | disclosed |
| WO-2013034761-A1 | PYRIDINE COMPOUNDS AND USES THEREOF | H. LUNDBECK A/S (DK) | 2013-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235645-A1 | Pyridine Compounds and Uses Thereof | ATP6V1B2, NDUFS5, MT-ND5 | PDE2A 719/4885PDE10A 476/4885KDM4E 1145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.